Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Published byJudith Logan Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive."— Presentation transcript:

1 Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive breast cancer (B), and ER-positive breast cancer (C). Pathologic assessment in triple-negative breast cancer (D), HER2-positive breast cancer (E), and ER-positive breast cancer (F). CR = complete response, ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2 Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive breast cancer (B), and ER-positive breast cancer (C). Pathologic assessment in triple-negative breast cancer (D), HER2-positive breast cancer (E), and ER-positive breast cancer (F). CR = complete response, ER = estrogen . . . Korean J Radiol Sep-Oct;16(5):

Download ppt "Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive."

Similar presentations

Triple-Negative Breast Cancer

Triple-Negative Breast Cancer
Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.

Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.

Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < 0.0001(Log-rank) a Months Low gene expression.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.
P

P
Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups.

Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups.
Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,

Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,
Volume 34, Pages 122-130 (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.

Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.
Number of brain metastasis

Number of brain metastasis
Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic.

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic.
Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer  Victor E. Chen, BS, Erin.

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer  Victor E. Chen, BS, Erin.
TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES

TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,
Prognostic significance of tumor subtypes in male breast cancer:

Prognostic significance of tumor subtypes in male breast cancer:
Volume 165, Issue 5, Pages (May 2001)

Volume 165, Issue 5, Pages (May 2001)
Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.
A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

Similar presentations

Ads by Google